# Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg

> **NCT06233045** · PHASE1 · UNKNOWN · sponsor: **Bio-innova Co., Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Dapagliflozin-Test product
- **DRUG:** Dapagliflozin-Reference product

## Key facts

- **NCT ID:** NCT06233045
- **Lead sponsor:** Bio-innova Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-07-23
- **Primary completion:** 2024-08-25
- **Final completion:** 2024-09-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06233045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06233045, "Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06233045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*